The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study

Authors

Samantha Howe, research assistant, University of Melbourne*, slhowe@student.unimelb.edu.au #

Joshua Szanyi, doctor, University of Melbourne*, joshua.szanyi@unimelb.edu.au

Tony Blakely, Professor, University of Melbourne*, antony.blakely@unimelb.edu.au

*Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, 207 Bouverie Street, Carlton, VIC, 3053

#Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Statements

Copyright/license for publication: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Competing interests declaration: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare the following interests: the Population Interventions research group has received payment from Moderna Inc. to fund research into COVID-19 vaccine effectiveness in Victoria, Australia. The authors declare no other relationships or activities that could appear to have influenced the submitted work.

Contributorship statement: All authors contributed to planning the study design. Samantha Howe (SH; guarantor) conducted the literature search and quantitative analysis, with assistance from Tony Blakely (TB) and Joshua Szanyi (JS). All authors contributed equally to editing the final paper. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Transparency statement: SH affirms that this manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted, and any discrepancies from the study as planned have been explained.

Funding: no funding

Sponsors: no sponsors

Ethical approval: This study did not require ethical approval.

Patient and public involvement: This study included no patient/public involvement.

Trial registration: N/A
Abstract

Objectives
To quantify the morbidity impact of long COVID in Australia during the 2021-2022 Omicron wave in comparison to acute COVID-19 morbidity and mortality, and to other causes of morbidity and mortality in Australia.

Design
Burden of disease study using inputs from previously published population-based case-control, cross-sectional, or cohort studies.

Setting
Australia

Participants
People with symptomatic COVID-19 infection from 10/12/21 to 09/04/22.

Main outcomes measured
Years lived with disability (YLDs) from acute COVID-19 and long COVID measured as the product of the prevalence, duration and severity of each long COVID symptom determined from existing literature, summed across all long COVID symptoms and applied to the population of COVID-19 surviving cases in Australia during the 2021-2022 Omicron wave. Additionally, acute COVID YLDs and years of life lost from COVID deaths were estimated to generate total COVID-19 disability-adjusted life years (DALYs).

Results
During the Omicron wave in Australia, 5,300 (95% uncertainty interval [UI] 2,200-8,400) YLDs were attributable to long COVID, accounting for 74% of the overall YLDs from COVID-19 infections in this period.

The overall DALYs due to COVID-19 in this four-month period were 51,000 (95% UI 21,000-80,900), comprising 2.4% of total DALYs. This is comparable to the health loss caused by dementia and drug use disorders.

Conclusion
Long COVID requires consideration in pandemic policy planning given it is responsible for the majority of the total morbidity loss from COVID-19, even during an Omicron wave in a highly vaccinated population. Further research into the symptom profile and duration of long COVID following Omicron infection, and more robust severity measurement, will allow for more accurate estimation of long COVID morbidity.
**Summary box**

**What is already known on this topic**
Long COVID symptoms are known to occur for a proportion of acute COVID-19 survivors, with a greater risk existing for those unvaccinated and with a more severe acute infection. The health loss attributed to long COVID in the population throughout 2020-2021 has previously been estimated using existing health states to characterise this group of outcomes.

**What this study adds**
Our study is the first to comprehensively estimate long COVID morbidity, by its individual symptoms, during the 2021-2022 Omicron wave in Australia. Long COVID contributes to almost three-quarters of the non-fatal health loss resulting from Omicron variant infections, and should therefore be more explicitly considered in future pandemic policymaking.
**Introduction**

A post-acute phase of COVID-19, commonly termed long COVID, occurs among some individuals following acute SARS-CoV-2 infection. Long COVID describes the persistence and/or emergence of a heterogeneous group of symptoms at least 12 weeks after acute infection.\(^1\)\(^2\) There is no current consensus on the symptom profile that specifically characterises long COVID – the World Health Organisation’s current definition only states that for any symptoms occurring 12-weeks post-infection, other causes must be ruled out to allow for a long COVID diagnosis.\(^2\)

Comparisons have been made between long COVID and chronic fatigue syndrome (CFS), as fatigue, muscle weakness, and concentration difficulty are frequently reported among individuals with long COVID.\(^3\)\(^4\) However, various other symptoms unique to long COVID have been identified (Table 1).\(^5\) While some studies report symptom clustering, the frequency and significance of this remains unclear and individuals most commonly report experiencing one or two symptoms.\(^4\)\(^6\)\(^7\) The aetiology of long COVID is proposed to be related to continued immune activation and persistence of the virus itself in the various organ systems infected during the acute period.\(^8\) Numerous risk factors for long COVID have been identified, including a propensity towards an autoimmune response, female sex, co-morbidities such as Type 2 Diabetes Mellitus, and a more severe acute infection.\(^7\)\(^9\) Importantly, COVID-19 vaccination has been found to reduce the risk of long COVID.\(^10\)\(^11\)

**Table 1: Commonly reported long COVID symptoms**

<table>
<thead>
<tr>
<th>Organ system/symptom group</th>
<th>Symptoms</th>
</tr>
</thead>
</table>
| Cardiopulmonary            | Dyspnoea  
Cough  
Sore throat  
Chest pain  
Pulitations |
| Musculoskeletal            | Muscle weakness  
Muscle/joint pain |
| Neurological               | Concentration difficulty (‘brain fog’)  
Memory impairment  
Headache  
Impaired senses of taste/smell (dysosmia/dysgeusia) |
| Psychological              | Depression  
Anxiety  
Insomnia  
COVID-19 related post-traumatic stress disorder |
| Gastrointestinal           | Diarrhoea  
Changes to appetite |
| Other/general symptoms     | Fatigue  
Hair loss  
Skin rashes |

Given ongoing high rates of SARS-CoV-2 transmission globally, it is important to be able to quantify the full health impact of COVID-19, including its longer-term consequences. Recent burden of disease studies have attempted to estimate the health loss resulting from long COVID. These studies have treated long COVID as a single outcome and have most commonly utilised the Global Burden of Disease (GBD)
study health state of ‘post-acute consequences’ of other respiratory illnesses, or CFS, to approximate its severity. While these health states have some overlap with documented long COVID symptoms, they do not acknowledge the full breadth of symptoms linked to long COVID (Table 1), or the heterogeneity of symptoms reported between individuals.

A lack of high-quality evidence regarding the prevalence and duration of symptoms also limits quantification of the burden of long COVID. Many studies of long COVID lack an appropriate control group, or are subject to other methodological issues. Selection bias, for example, can result from self-selection into studies by those experiencing ongoing symptoms and loss-to-follow-up by those who are no longer symptomatic. There is also a risk of recall bias, and further information bias due to subjective symptom reporting, and non-blinding of cases to their COVID-19 diagnosis. While these biases are more likely to inflate estimates of long COVID prevalence, the opposite may occur in studies that have insufficient follow-up time to capture the full occurrence of long COVID symptoms, which are often relapsing and remitting in nature. In addition, the majority of published long COVID research was conducted in cohorts of unvaccinated, pre-Omicron variant infected cases. In order to accurately quantify the impact of long COVID, differences in risk resulting from these factors should be considered.

Therefore, this paper aims to answer the following research questions: firstly, what is the extent of the morbidity, in terms of occurrence rate, severity and duration, attributable to long COVID resulting from Omicron variant SARS-CoV-2 infections? Secondly, what proportion of total Disability-Adjusted Life Years (DALYs) accumulated during the 2021-2022 Omicron wave in Australia were due to long COVID, and how does this health loss compare to other major causes of disability in the country?

**Methods**

**Morbidity calculations**
Long COVID morbidity was calculated as follows, providing an estimate of the non-fatal health burden per initially symptomatic acute COVID-19 survivor attributable to long COVID:

\[
\text{Morbidity} = \text{Prevalence} \times \text{Duration} \times \text{Severity}
\]

A bottom-up approach was applied, separating long COVID into individual symptoms. The prevalence of each symptom (calculated as a risk difference in symptom frequency between COVID-19 survivors and COVID-negative controls) and duration (from 1 week post-infection for mild/moderate cases, and 4-weeks post-infection for those hospitalised), were extracted from the literature (Appendix 1). For each symptom, an estimate of severity, as a disability weight (DW), was taken from the GBD study. Some long COVID symptoms do not have direct health states for which DWs exist in the GBD – in these cases, best estimates have been determined from related health states. For example, the DWs of other sensory conditions (mild hearing loss and mild presbyopia) have been used as proxies for the DWs of dysosmia and dysgeusia.
A combinatorial approach was then used, with symptoms assumed to occur independently, allowing the prevalence of each pair of two symptoms and the residual prevalence of each symptom in isolation to be calculated. The joint probability of having three or more symptoms was considered to be low so was not included. A multiplicative adjustment for combining DWs for each symptom combination was applied, as shown below.21

\[
\text{Combined prevalence} = \text{Frequency}_{\text{Symptom } A} \times \text{Frequency}_{\text{Symptom } B}
\]

\[
\text{Combined DW} = 1 - (1 - \text{DW}_{\text{Symptom } A}) \times (1 - \text{DW}_{\text{Symptom } B})
\]

The morbidity for each individual symptom, and each group of two symptoms, were summed to obtain an overall estimate of the total ‘average’ morbidity loss from long COVID per initially symptomatic COVID-19 case. It is assumed that only initially symptomatic patients are at risk of long COVID.22 Full calculations are detailed in Appendix 2.

Given existing literature, the above ‘base case’ morbidity estimates were calculated for a population of unvaccinated individuals infected with a pre-Omicron variant of SARS-CoV-2, separately for three sub-groups: adult community cases, adult hospitalised cases, and children (any acute disease severity).6,17-19 Long COVID prevalence among previously hospitalised adults is approximately twice that among community cases.17 Symptom prevalence is also lower among children (0-17 years) compared to adults.19

Base case symptom prevalence estimates were then multiplied by an odds ratio (OR) of 0.55 to approximate symptom prevalence among vaccinated cases. This was based on findings from two recent studies that found reduced odds of symptoms following the acute infection by 49% and 41%, for those who had at least two COVID-19 vaccines compared to one/no vaccines.10,11 Vaccination post-infection has been found to have a limited effect on long COVID occurrence – therefore, only vaccination prior to infection was considered.23,34 Separately, prevalence estimates were further multiplied by an OR of 0.25 to represent Omicron-infected cases, based on an estimate of the reduction in risk of any symptoms at least 4-weeks post-infection for Omicron variant compared to Delta variant infections in a vaccinated cohort in the United Kingdom (UK).25 It is assumed that this association remains beyond 12 weeks post-infection. The exception to the latter multiplier was adults hospitalised with an Omicron infection – it was assumed that once a case is severe enough to be hospitalised, there is no difference in resulting long COVID compared to pre-Omicron variants.

Duration was applied differentially by acute COVID-19 severity, based on recent findings by Wulf Hansen et al., who reported a median duration of symptoms for community infections of 4 months, and 8.9 months for previously hospitalised cases.26 Exceptions to this have been applied to psychological symptoms, for which a shorter duration is estimated, as well as for children (see Table 2).18,19,27

Uncertainty in base case long COVID estimates was initially estimated by applying a standard deviation of +/- 20% to overall long COVID morbidity estimates (this
approximated the uncertainty we estimated using a comprehensive bottom-up approach, detailed in Appendix 3). For morbidity calculated for vaccinated and Omicron-infected sub-groups, a standard deviation of +/- 30% was applied to reflect a higher level of uncertainty in these estimates.

**Application to the Omicron wave and health burden comparison**

The total burden from COVID-19 cases during the first four months of the Omicron wave in Australia, defined here as December 10th 2021 to April 9th 2022, was calculated using DALYs (see equation below). DALYs are a cross-sectional measure of disease burden, counting a population’s morbidity loss in a given time period and the mortality due to deaths in that period. For COVID-19, DALYs in a given year would encompass both acute cases and deaths occurring in that year, as well as the burden from long COVID experienced in that year (including that from infections that occurred in previous years). A difference to usual burden of disease methods applied here was that morbidity includes that generated during the four-month Omicron wave, as well as future predicted morbidity from long COVID for those cases.

\[D A L Y = Y L L + Y L D\]

Years lived with disability (YLD) were calculated as the sum of long and acute COVID-19 morbidity, per symptomatic COVID-19 case. Existing acute COVID-19 morbidity estimates were updated to reflect current knowledge of Omicron infection symptom duration and severity across patient sub-groups (Appendix 4). Years of life lost (YLLs) due to COVID-19 deaths were estimated using standard burden of disease methods, multiplying deaths due to COVID-19 with the average remaining life expectancy of those who died (with reference life expectancy by sex and age obtained from the 2019 GBD, retrieved from the Institute for Health Metrics and Evaluation [IHME] results tool). This approach assumes no future changes to all-cause mortality rates, no difference in the mortality rates for those who die of COVID-19 and no discounting of YLLs. YLL and YLD calculations were applied to Omicron wave case numbers in strata of age, hospitalisation status and vaccination. Long COVID morbidity, and total COVID-19 DALYs were then compared to the leading causes of YLDs and DALYs in Australia, according to the GBD 2019.

**Patient and public involvement**

This study did not include patient or public involvement, using only already published literature.

**Results**

**Morbidity estimates**

Long COVID morbidity prevalence and decay over time for each symptom, for unvaccinated pre-Omicron infection, are presented in Appendix 5. Table 2 shows the DW used for each symptom, and the estimated prevalence of that symptom among Omicron infected, unvaccinated cases; the prevalence among vaccinated cases is that shown multiplied by 0.55.
Table 2: Health states & prevalence estimates applied for each long COVID symptom, among Omicron-infected (unvaccinated) cases

<table>
<thead>
<tr>
<th>Sequelae</th>
<th>DW (95% CI)</th>
<th>Health state/justification</th>
<th>Prevalence among Omicron cases (unvaccinated)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Adults</td>
<td>Community</td>
</tr>
<tr>
<td>Dyosmia</td>
<td>0.01 (0.004-0.020)</td>
<td>Health state: hearing loss, mild &amp; presbyopia. Assumed to be equivalent to mild impairment of other senses.</td>
<td>2.6%</td>
</tr>
<tr>
<td>Dygeusia</td>
<td>0.01 (0.004-0.020)</td>
<td>Health state: hearing loss, mild &amp; presbyopia. Assumed to be equivalent to mild impairment of other senses.</td>
<td>2.1%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.051 (0.036-0.062)</td>
<td>Health state: infectious disease, post-acute consequences (adjusted down for depression and pain). No reasonable estimate exists for fatigue in GBD study 2019, however reasonable estimates exist for muscle/joint pain, and depression. Therefore, DW applied in the present study for depression and muscle/joint pain were subtracted from ‘post-acute consequences’ DW (DW=0.219 [95% CI 0.148-0.308]), which is characterised by weakness/tiredness, depression and body pain.</td>
<td>2.0%</td>
</tr>
<tr>
<td>Dysnoea</td>
<td>0.019 (0.011-0.033)</td>
<td>Health state: chronic obstructive pulmonary disease (COPD) and other chronic respiratory problems, mild.</td>
<td>1.1%</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0.011 (0.005-0.021)</td>
<td>Health state: abdominopelvic problem, mild. Assumed to be equivalent to gastroesophageal reflux disease (GERD).</td>
<td>0.5%</td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>0.004 (0.001-0.008)</td>
<td>Health state: anaemia, mild. Mild anaemia characterised by feeling slightly weak/tired.</td>
<td>1.0%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0.032 (0.021-0.046)</td>
<td>Health state: vertigo (adjusted to estimate ‘mild’ vertigo health state). Assumed that dizziness is mild form of vertigo – as there is no ‘mild’ vertigo DW, ‘vertigo’ DW (DW=0.113 [95% CI: 0.074-0.158]) was multiplied by 0.29 (average</td>
<td>0.6%</td>
</tr>
<tr>
<td>Condition</td>
<td>Estimated Ratio (95% CI)</td>
<td>Health State Description</td>
<td>Prevalence Vaccine</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Muscle/joint pain</td>
<td>0.023 (0.013-0.037)</td>
<td>Health state: musculoskeletal problems, lower limbs, mild.</td>
<td>0.8%</td>
</tr>
<tr>
<td>Headache</td>
<td>0.037 (0.022-0.057)</td>
<td>Health state: headache, tension-type.</td>
<td>0.8%</td>
</tr>
<tr>
<td>Numb/tingling limbs</td>
<td>0.023 (0.013-0.037)</td>
<td>Health state: musculoskeletal problems, lower limbs, mild.</td>
<td>0.8%</td>
</tr>
<tr>
<td>Concentration difficulty</td>
<td>0.069 (0.046-0.099)</td>
<td>Health state: dementia, mild.</td>
<td>1.9%</td>
</tr>
<tr>
<td>Memory impairment</td>
<td>0.069 (0.046-0.099)</td>
<td>Health state: dementia, mild.</td>
<td>1.4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0.03 (0.018-0.046)</td>
<td>Health state: anxiety disorder, mild. Anxiety disorder is characterised by difficulty sleeping and concentrating.</td>
<td>1.3%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>0.03 (0.018-0.046)</td>
<td>Health state: anxiety disorder, mild.</td>
<td>N/A</td>
</tr>
<tr>
<td>Depression</td>
<td>0.145 (0.099-0.209)</td>
<td>Health state: major depressive disorder, mild.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Children**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Estimated Ratio (95% CI)</th>
<th>Health State Description</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysosmia</td>
<td>0.01 (0.004-0.020)</td>
<td>Health state: hearing loss, mild &amp; presbyopia. Assumed to be equivalent to mild impairment of other senses.</td>
<td>2.0%</td>
</tr>
<tr>
<td>Headache</td>
<td>0.037 (0.022-0.057)</td>
<td>Health state: headache, tension-type.</td>
<td>1.3%</td>
</tr>
<tr>
<td>Eye soreness</td>
<td>0.011 (0.005-0.02)</td>
<td>Health state: presbyopia. No health states eye pain exist in GBD study 2019, therefore estimated from presbyopia (characterised by mild near vision loss).</td>
<td>0.5%</td>
</tr>
<tr>
<td>Sore throat</td>
<td>0.006 (0.002-0.012)</td>
<td>Health state: infectious disease, acute episode, mild. Assumed to be equivalent to mild upper respiratory infection.</td>
<td>0.5%</td>
</tr>
<tr>
<td>Cognitive difficulty</td>
<td>0.045 (0.028-0.066)</td>
<td>Health state: attention deficit hyperactivity disorder (ADHD). ADHD is characterised by difficulty with concentration and memory.</td>
<td>0.8%</td>
</tr>
</tbody>
</table>

* Multiply by 0.55 (on odds scale) to obtain prevalence among vaccinated.
* Symptom prevalence among initially hospitalised COVID-19 cases does not differ between pre-Omicron and Omicron variants, as outlined in the Methods.
* DW applied is not directly taken from a DW in the 2019 GBD, instead estimated by adjusting existing DWs.
* Community and hospitalised sub-groups for cognitive symptoms are achieved through weighting of estimates from mild vs. severe sub-groups as measured by Caspersen et al.
* Children are not separated by severity of acute infection.

Health states applied were obtained from the 2019 GBD study. CI = Confidence Interval; DW= Disability Weight; GBD= Global Burden of Disease.
The total long COVID morbidity estimates for each sub-group are shown in Table 3.

### Table 3: Long COVID morbidity loss expected for any COVID-19 case (where morbidity loss is the proportionate loss in quality of life over 1 year compared to full health)

<table>
<thead>
<tr>
<th>Population group</th>
<th>Morbidity estimate (95% UI)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unvaccinated</td>
<td>Vaccinated</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-hospitalised</td>
<td>0.0017 (0.0007-0.0026)</td>
<td>0.0009 (0.0004-0.0014)</td>
</tr>
<tr>
<td>Hospitalised</td>
<td>0.0348 (0.0144-0.0553)</td>
<td>0.0143 (0.0059-0.0227)</td>
</tr>
<tr>
<td>Children</td>
<td>0.0003 (0.0001-0.0004)</td>
<td>0.0001 (0.0001-0.0002)</td>
</tr>
</tbody>
</table>

Note the morbidity loss for someone actually with long COVID is much greater than shown here, as these are estimates of expected morbidity loss for any surviving COVID-19 case. 95% UI estimated using +/- 30% standard deviation. UI= Uncertainty Interval

### Application to the Omicron wave

Some 4.87 million COVID-19 cases were notified in Australia during the first four months of the Omicron wave, with approximately 35,500 hospitalisations and 3,463 deaths. An estimated 61% of notified cases were vaccinated at the time of infection (Appendix 6).

The overall morbidity (i.e. YLDs) resulting from infections in this period, including acute and long COVID is shown in Figure 1. Long COVID accounts for approximately 74% of the overall non-fatal COVID-19 health loss among notified cases during the first 4 months of the Australian Omicron wave, at 5,300 YLDs (95% uncertainty interval [UI] 2,200- 8,400 YLDs).
Figure 1: COVID-19 morbidity resulting directly from Omicron cases during the first 4-months of the Omicron wave, December 10th 2021-April 9th 2022.

95% uncertainty intervals are shown for long COVID YLD estimates, measured with +/- 30% standard deviation.

Total morbidity (rightmost bar) is estimated at 7,100 YLDs.

YLDs= Years Lived with Disability

The overall DALYs resulting from COVID-19 infections in the four-month period was estimated at 51,000 (95% UI 21,000 to 80,900), of which long-COVID contributed 10.4% (compared to the acute COVID-19 morbidity contribution of 3.5%).

The leading 25 causes of morbidity in Australia ranked by YLDs are presented in Figure 2 along with the estimated YLDs resulting from COVID-19 cases during the first four months of the Omicron wave. Total COVID-19 morbidity is ranked 24th, comparable to the non-fatal health loss resulting from chronic kidney disease.
Figure 2: Comparison of top YLD causes in Australia (GBD 2019) to YLDs from COVID-19, during the first 4 months of the Omicron wave (December 10th 2021-April 9th 2022).

COVID-19 YLDs, separated as long COVID (blue) and acute COVID-19 (red) includes the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID YLD estimates, measured using +/- 30% standard deviation. YLDs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period.20

COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; T2DM= Type 2 Diabetes Mellitus; YLD= Years Lived with Disability.

The leading 25 causes of morbidity and mortality in Australia ranked by DALYs, are presented in Figure 3 along with the estimated DALYs resulting from the first four months of the COVID-19 Omicron wave. The DALYs resulting from COVID-19 cases are estimated to be 2.4% of all expected DALY loss in the four months, and rank 10th among conditions (between Alzheimer’s and other dementias, and drug use disorders). The 95% uncertainty interval indicates that the rank could in fact be as high as 3rd (between low back pain and falls) or as low as 24th (below alcohol use disorders).
Figure 3: Comparison of top DALY causes in Australia (GBD 2019) to DALY from long COVID, and total COVID-19, during the first 4 months of the Omicron wave (December 10th 2021-April 9th 2022).

COVID-19 DALYs, separated as YLD (purple) and YLL (red), include the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID DALYs, measured using +/- 30% standard deviation. DALYs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period. COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; DALY= Disability-Adjusted Life Years; T2DM= Type 2 Diabetes Mellitus.

Discussion

This is the first publication to quantify the overall health burden of COVID-19 throughout the Omicron wave in Australia. We found that long COVID contributed to approximately 74% of the non-fatal health loss resulting from COVID-19 infections in the first four months of this wave; with the total YLDs comparable to that caused by chronic kidney disease and ischaemic heart disease (Figure 2). Also significant is the overall COVID-19 disease burden calculated in this study, amounting to 51,000 DALYs over the initial four months of the Omicron wave, or the 10th highest cause of DALYs in a 4-month period in Australia (Figure 3).

The strengths of this study lie in the comprehensive approach applied to quantify long COVID morbidity across multiple patient sub-groups, and consideration of the impact of vaccination and the Omicron variant on long COVID incidence. This has not been considered in other studies to our knowledge. Our approach also allows for consideration of a more complete profile of symptoms, rather than only those
corresponding to existing health states. The health state ‘post-acute consequences’, applied by two recent Australian publications to estimate the long COVID health burden in Australia, encompasses fatigue, depression and body pain.\textsuperscript{12,14,20} By treating long COVID as a single outcome, these studies assume that the average long COVID sufferer has all the symptoms included within this applied health state.

This study has limitations. Long COVID is an area of rapidly emerging and evolving research, characterised by limited high-quality literature. As such, there is a high level of uncertainty in our findings. The studies utilised for our prevalence estimates were included based on an assessment of bias and methodological quality – however, prevalence may still be overestimated, partly due to the inherent risk of bias in long COVID studies, and the assumptions made given the lack of long-term data on Omicron infections. However, a recent study by the IHME quantified long COVID parameters across three separate symptom groups (cognitive difficulty, fatigue, and shortness of breath).\textsuperscript{26} In a supplementary analysis (Appendix 7), we calculated long COVID morbidity with the IHME’s estimates, and found comparable results.

One-way sensitivity analyses conducted to determine the contribution of each morbidity parameter to overall uncertainty in long COVID morbidity, found the greatest contribution came from severity estimates (Appendix 8). This is of concern, given that the majority of DWs applied were made by estimation from other health states, and were applied consistently across sub-groups.\textsuperscript{20} Additionally, cognitive and psychological symptoms both contributed to a high level of uncertainty in overall estimates, despite only being a small proportion of the overall symptoms included in this analysis, indicating a need for further research on the prevalence and severity of these symptoms (Appendix 8).\textsuperscript{6,18}

It is important to note that many people dying of COVID-19 have co-morbidities, so their true YLLs will be less than that measured using standard DALY methods, which assumes those dying of COVID-19 have the mortality rate specified in the reference life table.

Our findings enable further understanding of the health impact from COVID-19 infections and highlight the need to factor in long COVID-related health loss when making policy decisions, in the context of the continuing Omicron wave. Whilst the prevalence of long COVID symptoms is less now among highly vaccinated populations with Omicron than it was for pre-Omicron variants among unvaccinated populations, long COVID still contributes substantial health loss when summed over all infections. The knowledge from this paper may therefore provide an imperative for policymakers to better address the healthcare needs of long COVID sufferers – few evidence-based management options currently exist.\textsuperscript{36,37} Specific areas of need may require prioritisation, for example psychological support for those previously hospitalised with COVID-19, for whom such symptoms are relatively common.\textsuperscript{18}

Our analysis focused on long COVID symptoms occurring in the months following infection. However, SARS-CoV-2 infection has also been associated with persistent organ damage, and an increased risk of chronic conditions including Type 2 Diabetes Mellitus and cardiovascular disease, particularly among those who had a severe acute infection.\textsuperscript{38-42} Longer-term research will be required in the future to determine the extent that SARS-CoV-2 infection causes these outcomes; if COVID-19 acts as a risk
factor for other conditions in the long-term, this downstream health loss could exceed that attributed to long COVID.

It is necessary to conduct further research into the long COVID symptom parameters applied in this study, across sub-groups. For example, the impact of vaccination over a longer timeframe should be addressed – waning vaccine protection against infection and acute outcomes is known to occur, but the impact of waning immunity on long COVID occurrence is yet to be researched thoroughly. Improved symptom severity ascertainment should also be a priority to improve current estimations, given the uncertainty in the DW approach applied. Knowing with greater certainty the health loss that results from long COVID, in a growing population who have been infected with SARS-CoV-2, may determine future policy decisions surrounding COVID-19 safety measures and healthcare planning.
Acknowledgements: expert knowledge was kindly provided by Professor John D. Potter (Massey University, Wellington, Fred Hutchinson Cancer Research Centre, Seattle, Washington and University of Washington, Seattle, Washington)

Data sharing statement: relevant data/sources used for quantitative analysis can be made available by authors on request.
References


